Inhibikase Therapeutics Inc.
Organization details
- Legal name
- Inhibikase Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Wilmington
- Headquarters state / province
- Delaware
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IKT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001750149
- EIN
- 26-3407249
Board of directors
-
Amit Munshi · DirectorSince 2024
-
Arvind Kush · DirectorSince 2024
-
David Canner · DirectorSince 2024
-
Dennis N. Berman · DirectorSince 2023
-
Gisele Dion · DirectorSince 2023
-
Mark T. Iwicki · Director · Chief Executive OfficerSince 2025
-
Milton H. Werner · Director · President and CEOSince 2023
-
Paul C. Grint · DirectorSince 2023
-
Roberto Bellini · DirectorSince 2024
-
Roy Lester Freeman · DirectorSince 2023
-
Scott M. Wasserman · DirectorSince 2026
-
Vincent Aurentz · DirectorSince 2025
Chief executives
Director election results
Annual meeting of June 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
77.2%
-
84.6%
Board connections
3 of this board's directors also sit on 7 other boards. 6 are in the same sector.
-
Arcutis Biotherapeutics Inc. Same sectorvia Amit Munshi
- via Gisele Dion
-
Damora Therapeutics Inc. Same sectorvia Amit Munshi
-
Jade Biosciences Inc. Same sectorvia Mark T. Iwicki
-
KALA BIO Inc. Same sectorvia Mark T. Iwicki
-
Q32 Bio Inc. Same sectorvia Mark T. Iwicki
-
Zura Bio Limited Same sectorvia Amit Munshi
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,999,999
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 30, 2026 | Dennis N. Berman Director | Option exercise | +21,854 | $1.26 | $27,536 |
| Jul 29, 2026 | RA Capital Healthcare Fund LP 10% owner | Other | −18,030,000 | — | — |
| Feb 21, 2026 | Vincent Aurentz Director | Sold back to the company | −255,299 | — | — |
| Feb 21, 2026 | Christopher Cabell Officer (President & Head of R&D) | Sold back to the company | −338,282 | — | — |
| Feb 21, 2026 | Amit Munshi Director | Sold back to the company | −19,089 | — | — |
| Nov 21, 2025 | SANDS FRANK M. 10% owner | Open-market purchase | +2,068,965 | $1.45 | $2,999,999 |
| Feb 21, 2025 | Amit Munshi Director | Grant or award | +57,265 | — | — |
| Oct 21, 2024 | Roberto Bellini Director | Open-market purchase | +1,460,000 | $1.37 | $2,000,200 |
| Oct 21, 2024 | Arvind Kush Director | Open-market purchase | +145,000 | $1.37 | $198,650 |
| Oct 21, 2024 | Amit Munshi Director | Open-market purchase | +365,000 | $1.37 | $500,050 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Inhibikase Therapeutics Inc.
Who is the CEO of Inhibikase Therapeutics Inc.?
Mark T. Iwicki has been Inhibikase Therapeutics Inc.'s Chief Executive Officer since February 2025.
How many directors are on Inhibikase Therapeutics Inc.'s board?
Inhibikase Therapeutics Inc.'s board has 12 directors: Amit Munshi, Arvind Kush, David Canner, Dennis N. Berman, Gisele Dion, Mark T. Iwicki, Milton H. Werner, Paul C. Grint, Roberto Bellini, Roy Lester Freeman and 2 others.
Are Inhibikase Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Inhibikase Therapeutics Inc. insiders bought $3.0 million of shares in 1 purchase and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="inhibikase-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.